1 minute treatment update

Treatment pearls in your chosen speciality or topic, as they are published, updated every 48 hours.
Last updated on 2023/11/28.





Expert Opin Drug Saf 28 Nov. 2023.
Nail lichen planus treatment safety.

Topical therapies for nail lichen planus (clobetasol propionate, topical tacrolimus, bath-PUVA), intralesional treatment (triamcinolone), and systemic treatment (corticosteroids, retinoids, small molecule inhibitors (jak/stat inhibitors), TNF-alpha inhibitors (etanercept), systemic immunomodulators (oral calcineurin inhibitors, mycophenolate mophetil), and antimalarials (chloroquine), each with unique safety profiles and considerations. Herein, we discuss common and uncommon adverse events, as well as utilization for special populations, including pregnant and pediatric patients

 Pubmed Scholar sci-hub

Int J Dermatol 28 Nov. 2023.
Long-term maintenance treatment of rosacea: experts' opinion.

Maintenance phase success depends on patient's adherence to daily skin care, appropriate treatments, continued follow-up with dermatologist, and self-assessment to identify new signs and symptoms indicating disease relapse.

 Pubmed Scholar sci-hub

J Cosmet Dermatol 27 Nov. 2023.
Treatment of periorbital aging with negative pressure fractional microneedle radiofrequency: A self-controlled clinical trial.

NPMFR could be an effective and safe treatment modality for the treatment of periorbital aging.

 Pubmed Scholar sci-hub

Annu Rev Immunol 27 Nov. 2023.
B Cell-Directed Therapy in Autoimmunity.

annualreviews.org/page/journal/pubdates for revised estimates

 Pubmed Scholar sci-hub

Biomed Pharmacother 26 Nov. 2023.
Personalized neoantigen-based T cell therapy triggers cytotoxic lymphocytes expressing polyclonal TCR against metastatic ovarian cancer.

Notably, the neoantigen-specific TCR clonotypes persisted in the peripheral blood after cell therapy. Our findings indicate that personalized neoantigen-based T cell therapy triggers cytotoxic lymphocytes expressing polyclonal TCR against ovarian cancer, suggesting its promising potential in cancer immunotherapy

 Pubmed Scholar sci-hub

Dermatitis 27 Nov. 2023.
The Risk of Herpes Virus Infection in Patients With Atopic Dermatitis During Biologic Therapy: A Retrospective Records Based Observational Study.

Sorry! No treatment pearl could be fetched.

 Pubmed Scholar sci-hub

Br J Dermatol 27 Nov. 2023.
Safety and Efficacy of Dual TYK2 Inhibitor and Monoclonal Antibody Therapy for Psoriasis and Psoriatic Arthritis.

Sorry! No treatment pearl could be fetched.

 Pubmed Scholar sci-hub

Clin Exp Dermatol 27 Nov. 2023.
Exacerbation of clinical manifestations of bullous pemphigoid after treatment with dupilumab.

Sorry! No treatment pearl could be fetched.

 Pubmed Scholar sci-hub

J Dermatolog Treat Dec. 2023.
An 8-year follow-up of IgG4-related skin disease presented with generalized ALHE-like eruptions: successful treatment of glucocorticoid and cyclophosphamide.

He was treated with oral glucocorticoid and cyclophosphamide, which resulted in complete remission. No relapse and disease progression were seen with a follow-up for 8 years

 Pubmed Scholar sci-hub

J Dermatolog Treat Dec. 2023.
A center-based, ambulatory care concept for hidradenitis suppurativa improves patient outcomes and is also cost-effectiveness.

Treatment costs of HS are substantial and increase with disease severity. The new form of care is cost-effective and is expected to decrease costs in the long run.

 Pubmed Scholar sci-hub

Int J Dermatol 27 Nov. 2023.
Associating personal and cultural reflections of identity with mental health status may cause more harm than help: a response to previous publication.

Sorry! No treatment pearl could be fetched.

 Pubmed Scholar sci-hub

J Eur Acad Dermatol Venereol 27 Nov. 2023.
A comprehensive review of nondermatophyte mould onychomycosis: Epidemiology, diagnosis and management.

Terbinafine and itraconazole therapy (continuous and pulsed) appear effective to varying extents for treating onychomycosis caused by Aspergillus, Fusarium or Scopulariopsis. There is scant literature on oral treatments for Neoscytalidium

 Pubmed Scholar sci-hub

J Dermatol 27 Nov. 2023.
New treatment of pyoderma gangrenosum and hidradenitis suppurativa: A review.

When resistance to biologics emerges, a combined approach targeting multiple overactive cytokines with immunosuppressants, for example cyclosporine and Janus kinase inhibitors, could be an option. In the current review, we explore recent therapeutic developments for PG and HS

 Pubmed Scholar sci-hub

J Dermatol 27 Nov. 2023.
Pyoderma gangrenosum successfully treated with split-thickness skin grafting in combination with negative pressure wound therapy: A case report.

Sorry! No treatment pearl could be fetched.

 Pubmed Scholar sci-hub

J Dermatol 27 Nov. 2023.
Favorable efficacy of S-1 treatment for locoregionally advanced cutaneous squamous cell carcinoma in the head and neck region.

S-1 showed favorable efficacy and low toxicity in patients with head and neck locoregionally advanced cutaneous squamous cell carcinoma. S-1 may be a good alternative to the anti-PD-1 antibody for treating head and neck locoregionally advanced squamous cell carcinoma

 Pubmed Scholar sci-hub

J Dermatol 27 Nov. 2023.
Management of severe allergy, reacting to acetaminophen and small doses of cyclooxygenase-2 inhibitor.

Sorry! No treatment pearl could be fetched.

 Pubmed Scholar sci-hub

J Dermatol 27 Nov. 2023.
Pulsed-dye laser as an effective treatment for recalcitrant granulomatous rosacea and a potential regulator of CXCL9 expression.

These findings suggest that PDL may modulate CXCL9 secretion in fibroblasts, potentially limiting the recruitment of immune cells to the lesion. Although further research is needed to fully understand the precise mechanisms underlying the role of CXCL9 in GR, PDL may be a promising therapeutic approach for refractory GR

 Pubmed Scholar sci-hub

J Drug Target 27 Nov. 2023.
Clinical Evaluation of Liposome-based Gel Formulation Containing Glycolic Acid for the Treatment of Photodamaged Skin.

Moreover, liposomal gel formulation was able to minimize side effects of GA. According to the obtained results, the liposome-based gel formulation can be used as potential drug delivery system to enhance permeation of GA through skin layers and also reduce its side effects

 Pubmed Scholar sci-hub

J Dtsch Dermatol Ges 27 Nov. 2023.
Long-term remission with rituximab therapy in a five-year-old patient with pemphigus vulgaris.

Sorry! No treatment pearl could be fetched.

 Pubmed Scholar sci-hub

J Cosmet Dermatol 27 Nov. 2023.
Facial segmental lipoatrophy effectively treated with a deep priming filler incorporating calcium hydroxyapatite with results sustained for 12 months.

Sorry! No treatment pearl could be fetched.

 Pubmed Scholar sci-hub